ClinicalTrials.gg
CompletedNCT01126580Updated Jan 16, 2015Results posted

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

A Phase 3 interventional study of Metformin and LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 91 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
807
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
7th of 54
807 · median 159
Started
2010
with 6 others
Phase 3
22 of 54
1 open now
Registered
7th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.

Read the detailed description

The term rescue therapy in this trial was defined primarily as additional nontrial antidiabetic medication for the management of severe, persistent hyperglycemia or alternative antidiabetic medication following study drug discontinuation. For efficacy analyses, participants who received rescue medication were included in the analysis population, but only measurements obtained prior to taking rescue therapy were included in the efficacy analysis. For safety analyses, with the exception of hypoglycemia outcomes, all measurements including those obtained after taking rescue therapy were included in the analysis.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes for greater than or equal to 3 months and less than or equal to 5 years based on the disease diagnostic criteria (refer to the World Health Organization's [WHO] Classification of Diabetes).
  • Are treatment-naïve, not optimally controlled with diet and exercise alone, or are taking 1 oral antihyperglycemic medication (OAM) as monotherapy (excluding thiazolidinediones). For those on 1 OAM, the dose must be less than or equal to 50% the maximum authorized per local label.
  • Are able and willing to tolerate a minimum dose of 1500 milligrams per day (mg/day) or up to 2000 mg/day of metformin.
  • Have glycosylated () greater than or equal to 6.5% to less than or equal to 9.5%.
  • Females of (not surgically sterilized and between menarche and 1-year ) must: a) test negative for pregnancy at screening based on a serum pregnancy test, and b) agree to use a reliable method of during the study and for 1 month following the last dose of study drug; or c) not be breastfeeding.
  • Have a stable weight (plus or minus 5%) greater than or equal to 3 months prior to screening.
  • Have a (BMI) between 23 and 45 kilograms per square meter (kg/m\^2), inclusive.
  • Are well-motivated, capable, and willing to: a) perform self-monitored blood glucose (SMBG) testing; b) learn how to self-inject treatment (LY2189265 or placebo) and c) maintain a study diary.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus.
  • Are being or have been treated with any of the following medications: a) chronically treated with insulin for the treatment of diabetes in the past; however, a short-term use of insulin more than 3 months prior to screening is allowable, b) glucagon-like peptide 1 (GLP-1) analogs within 3 months prior to this screening, c) drugs to cause weight loss within 3 months prior to screening, d) thiazolidinediones (TZDs) within 3 months prior to screening, e) chronically treated (greater than or equal to 14 days) with an oral or have received this type of therapy within 4 weeks prior to screening, or f) illegal drugs.
  • Have had 1 or more cases of uncontrolled diabetes that required hospitalization in the 6 months prior to screening.
  • Have stomach problems, have chronically taken medication to increase movement in the digestive tract or slow down the emptying of the digestive tract, or have had gastric bypass (bariatric) surgery.
  • Have had problems with the heart or brain in the past 2 months prior to screening, such as a heart attack, chest pain, heart failure, heart bypass operation, angioplasty or stent insertion, a heart rhythm problem, or a stroke.
  • Have a serum creatinine result which shows a greater than or equal to 1.5 milligrams per deciliter (mg/dL) for men or greater than or equal to 1.4 mg/dL for women.
  • Have a problem with the liver or pancreas.
  • Have a result which shows less than 60 milliliters per minute (mL/min), evidence of a significant active, uncontrolled endocrine (hormone), or active abnormality.
  • Have a serum calcitonin test which shows greater than or equal to 20 picograms per milliliter (pcg/mL) at the time of screening.
  • Have a family history of medullary C-cell hyperplasia or endocrine neoplasia type 2A or type 2B.
  • Have cancer (except for skin cancer) or have been in remission from cancer for less than 5 years.
  • Have had an organ transplant except for corneal transplant.
  • Have received treatment within the last 30 days with a drug which has not been regulatory approved.
  • Have participated in a medical, surgical, or pharmaceutical study where these types of procedures were performed within 30 days prior to screening.
  • Have any condition that is a to or would interfere with medications provided for this study to treat diabetes.
  • Have a blood disorder that would interfere with the drawing of blood glucose measurements or lab samples.
  • Have previously participated or signed an document for this same type of study and study drug.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
807 participants (actual)

Study arms

  • Experimental
    1.5 mg LY2189265

    LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52

    Drug: LY2189265 · Drug: Placebo (oral)

  • Experimental
    0.75 mg LY2189265

    LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52

    Drug: LY2189265 · Drug: Placebo (oral)

  • Active comparator
    Metformin

    Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52 Placebo: subcutaneously (SC), once weekly for 52 weeks

    Drug: Metformin · Drug: Placebo (subcutaneous)

Interventions

  • Also known as: Dulaglutide

  • DrugPlacebo (oral)
  • DrugPlacebo (subcutaneous)
06

What researchers measure

Primary outcomes

  1. Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 52 weeks

  2. Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks

    The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model.

    Time frame: 26 weeks and 52 weeks

  3. Change From Baseline to 26 and 52 Weeks in Fasting Blood Glucose

    Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, and 52 weeks

  4. Change From Baseline to 26 and 52 Weeks in Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles

    The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  5. Change From Baseline to 26 and 52 Weeks in Body Weight

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  6. Change From Baseline to 26 and 52 Weeks in Body Mass Index (BMI)

    Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  7. Change From Baseline to 26 and 52 Weeks in Homeostasis Model Assessment of Beta-cell Function

    The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, and 52 weeks

  8. Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL) Score

    The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

    Time frame: Baseline, 26 weeks, and 52 weeks

  9. Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP) Score

    The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

    Time frame: Baseline, 26 weeks, and 52 weeks

  10. Change From Baseline to 26 and 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Status Version

    The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

    Time frame: Baseline, 26 weeks, and 52 weeks

  11. Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version

    The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

    Time frame: 52 weeks

  12. Change From Baseline to 26 and 52 Weeks in the Diabetes Symptoms Checklist Participant-reported Outcome (DSC-r) Score

    The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5="extremely" to 1="not at all." For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

    Time frame: Baseline, 26 weeks, and 52 weeks

  13. Number of Participants With Treatment Emergent Adverse Events at 26 and 52 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: 26 weeks and 52 weeks

  14. Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, and 52 weeks

  15. Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate

    Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  16. Change From Baseline to 26 and 52 Weeks in Pulse Rate

    Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, and 52 weeks

  17. Change From Baseline to 26 and 52 Weeks in Blood Pressure

    Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks, and 52 weeks

  18. Percent Change From Baseline to 26 and 52 Weeks in Total Cholesterol

    Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

    Time frame: Baseline, 26 weeks, and 52 weeks

  19. Percentage Change From Baseline to 26 and 52 Weeks in High Density Lipoprotein Cholesterol (HDL-C)

    Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

    Time frame: Baseline, 26 weeks, and 52 weeks

  20. Percentage Change From Baseline to 26 and 52 Weeks in Low Density Lipoprotein Cholesterol (LDL-C)

    Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

    Time frame: Baseline, 26 weeks, and 52 weeks

  21. Percentage Change From Baseline to 26 and 52 Weeks in Triglycerides

    Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

    Time frame: Baseline, 26 weeks, and 52 weeks

  22. Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes

    Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.

    Time frame: Baseline, 26 weeks, and 52 weeks

  23. Change From Baseline to 26 and 52 Weeks in Serum Calcitonin

    Time frame: Baseline, 26 weeks, and 52 weeks

  24. Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies

    A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks.

    Time frame: Baseline through 52 weeks

  25. Number of Self-reported Hypoglycemic Events at 26 and 52 Weeks

    Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and 52 weeks

  26. Rate of Self-reported Hypoglycemic Events at 52 Weeks

    Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  27. Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks plus 30-day follow up

  28. Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks Plus 30-day Follow up

    Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks plus 30-day follow up

  29. Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)

    Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

    Time frame: 4 weeks, 13 weeks, 26 weeks, and 52 weeks

07

Results

Posted Jan 16, 2015

Participant flow

Participant flow — Overall Study
Milestone1.5 mg LY21892650.75 mg LY2189265Metformin
Started269270268
Received at least 1 dose of study drug269270268
Completed 26 weeks233242226
Completed220218213
Not completed495255
Withdrew: Adverse event14812
Withdrew: Withdrawal by subject111914
Withdrew: Sponsor decision547
Withdrew: Physician decision112
Withdrew: Entry criteria not met112
Withdrew: Lack of efficacy234
Withdrew: Protocol violation012
Withdrew: Lost to follow-up15139
Withdrew: Treatment non-compliance023

Outcome measures

PrimaryChange From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892650.75 mg LY2189265Metformin
Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)-0.78 ± 0.06-0.71 ± 0.06-0.56 ± 0.06
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = <0.001 (The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.22 · 95% CI -0.36 to -0.08
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = <0.001 (The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.15 · 95% CI -0.29 to -0.01
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.002 (Tree gatekeeping strategy to control the family-wise Type I error rate was applied.) · Ls mean difference: -0.22 · 95% CI -0.36 to -0.08
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.020 (Tree gatekeeping strategy to control the family-wise Type I error rate was applied.) · Ls mean difference: -0.15 · 95% CI -0.29 to -0.01
SecondaryChange From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892650.75 mg LY2189265Metformin
Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)-0.70 ± 0.07-0.55 ± 0.07-0.51 ± 0.07
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = <0.001 (The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.19 · 95% CI -0.35 to -0.02
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = <0.001 (The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.04 · 95% CI -0.20 to 0.12
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.024 (Tree gatekeeping strategy to control the family-wise Type I error rate was applied.) · Ls mean difference: -0.19 · 95% CI -0.35 to -0.02
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.299 (Tree gatekeeping strategy to control the family-wise Type I error rate was applied.) · Ls mean difference: -0.04 · 95% CI -0.20 to 0.12
SecondaryPercentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks

The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model.

Time frame:
26 weeks and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks
percentage of participants1.5 mg LY21892650.75 mg LY2189265Metformin
HbA1c less than 7%, 26 weeks61.562.653.6
HbA1c less than or equal to 6.5%, 26 weeks46.040.029.8
HbA1c less than 7%, 52 weeks60.053.248.3
HbA1c less than or equal to 6.5%, 52 weeks42.334.728.3
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · Regression, Logistic · p = 0.023 (Treatment comparison for HbA1c less than 7.0% at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Regression, Logistic · p = 0.021 (Treatment comparison for HbA1c less than 7.0% at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Regression, Logistic · p = 0.011 (Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Regression, Logistic · p = 0.001 (Treatment comparison for HbA1c less than 7% at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Regression, Logistic · p = 0.269 (Treatment comparison for HbA1c less than 7% at 52 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Regression, Logistic · p = 0.134 (Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in Fasting Blood Glucose

Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline to 26 and 52 Weeks in Fasting Blood Glucose
millimoles per liter (mmol/L)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=244, 247, 245)-1.61 ± 0.13-1.46 ± 0.13-1.34 ± 0.13
52 weeks (n=207, 210, 194)-1.56 ± 0.14-1.00 ± 0.14-1.15 ± 0.14
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.079 (Treatment comparison at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.451 (Treatment comparison at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.025 (Treatment comparison at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.402 (Treatment comparison at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles

The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline to 26 and 52 Weeks in Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles
millimoles per liter (mmol/L)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=195, 200, 211)-1.98 ± 0.15-1.75 ± 0.14-1.68 ± 0.14
52 weeks (n=197, 200, 212)-1.99 ± 0.16-1.71 ± 0.16-1.58 ± 0.15
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.061 (Treatment comparison at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.647 (Treatment comparison at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.022 (Treatment comparison at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.469 (Treatment comparison at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in Body Weight

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline to 26 and 52 Weeks in Body Weight
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=267, 269, 267)-2.29 ± 0.24-1.36 ± 0.24-2.22 ± 0.24
52 weeks (n=267, 269, 267)-1.93 ± 0.29-1.09 ± 0.29-2.20 ± 0.29
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.811 (Treatment comparison at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.003 (Treatment comparison at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.440 (Treatment comparison at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.001 (Treatment comparison at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in Body Mass Index (BMI)

Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · kilograms per meter squared (kg/m^2)
Change From Baseline to 26 and 52 Weeks in Body Mass Index (BMI)
kilograms per meter squared (kg/m^2)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks-0.86 ± 0.09-0.51 ± 0.09-0.82 ± 0.09
52 weeks-0.73 ± 0.11-0.42 ± 0.10-0.83 ± 0.11
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.750 (Treatment comparison at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.003 (Treatment comparison at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · ANCOVA · p = 0.412 (Treatment comparison at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · ANCOVA · p = 0.001 (Treatment comparison at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in Homeostasis Model Assessment of Beta-cell Function

The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · percentage of HOMA2
Change From Baseline to 26 and 52 Weeks in Homeostasis Model Assessment of Beta-cell Function
percentage of HOMA21.5 mg LY21892650.75 mg LY2189265Metformin
HOMA2-%B, 26 weeks (n=207, 207, 215)36.55 ± 3.4228.96 ± 3.4414.11 ± 3.37
HOMA2-%B, 52 weeks (n=179, 185, 170)29.97 ± 3.4622.5 ± 3.469.77 ± 3.51
HOMA2-%S, 26 weeks (n=207, 207, 215)0.95 ± 2.292.71 ± 2.299.99 ± 2.25
HOMA2-%S, 52 weeks (n=179, 185, 170)5.29 ± 2.431.84 ± 2.4310.83 ± 2.48
Statistical analysis
  • 1.5 mg LY2189265 vs Metformin · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-%B at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-%B at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Mixed Models Analysis · p = <0.001 (Treatment comparison of HOMA2-%B at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.003 (Treatment comparison of HOMA2-%B at 52 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.001 (Treatment comparison of HOMA2-%S at 26 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.010 (Treatment comparison of HOMA2-%S at 26 weeks.)
  • 1.5 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.077 (Treatment comparison of HOMA2-%S at 52 weeks.)
  • 0.75 mg LY2189265 vs Metformin · Mixed Models Analysis · p = 0.004 (Treatment comparison of HOMA2-%S at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL) Score

The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL) Score
units on a scale1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=247, 251, 247)0.09 ± 0.330.19 ± 0.320.02 ± 0.32
52 weeks (n=247, 252, 248)0.39 ± 0.33-0.05 ± 0.330.28 ± 0.33
SecondaryChange From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP) Score

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP) Score
units on a scale1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=248, 254, 249)0.72 ± 0.190.63 ± 0.180.79 ± 0.18
52 weeks (n=249, 255, 250)0.45 ± 0.190.61 ± 0.190.75 ± 0.19
SecondaryChange From Baseline to 26 and 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Status Version

The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Status Version
units on a scale1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=244, 249, 241)1.93 ± 0.391.81 ± 0.382.04 ± 0.39
52 weeks (n=245, 251, 244)1.82 ± 0.441.29 ± 0.431.94 ± 0.44
SecondaryDiabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version

The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

Time frame:
52 weeks
Reported as:
Least squares mean · units on a scale
Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version
units on a scale1.5 mg LY21892650.75 mg LY2189265Metformin
Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version12.92 ± 0.5212.73 ± 0.5012.58 ± 0.51
SecondaryChange From Baseline to 26 and 52 Weeks in the Diabetes Symptoms Checklist Participant-reported Outcome (DSC-r) Score

The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5="extremely" to 1="not at all." For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Diabetes Symptoms Checklist Participant-reported Outcome (DSC-r) Score
units on a scale1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=245, 253, 248)0.24 ± 0.36-0.16 ± 0.350.41 ± 0.35
52 weeks (n=247, 255, 249)0.49 ± 0.390.42 ± 0.390.59 ± 0.39
SecondaryNumber of Participants With Treatment Emergent Adverse Events at 26 and 52 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
26 weeks and 52 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events at 26 and 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks163150151
52 weeks179177170
SecondaryChange From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
milliseconds (msec)1.5 mg LY21892650.75 mg LY2189265Metformin
QTcF interval, 26 weeks (n=230, 237, 221)2.60 ± 1.171.38 ± 1.16-0.91 ± 1.18
QTcF interval, 52 weeks (n=212, 212, 205)3.76 ± 1.200.73 ± 1.19-0.53 ± 1.21
PR interval, 26 weeks (n=226, 235, 218)-0.04 ± 1.12-0.01 ± 1.10-2.04 ± 1.13
PR interval, 52 weeks (n=209, 210, 201)1.15 ± 1.181.53 ± 1.17-2.88 ± 1.19
SecondaryChange From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate

Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=230, 237, 221)1.60 ± 0.602.57 ± 0.590.82 ± 0.61
52 weeks (n=212, 212, 205)2.02 ± 0.662.36 ± 0.661.27 ± 0.67
SecondaryChange From Baseline to 26 and 52 Weeks in Pulse Rate

Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 26 and 52 Weeks in Pulse Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=244, 251, 239)2.39 ± 0.582.14 ± 0.571.59 ± 0.58
52 weeks (n=221, 219, 215)1.84 ± 0.571.63 ± 0.571.12 ± 0.57
SecondaryChange From Baseline to 26 and 52 Weeks in Blood Pressure

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · milliliters of mercury (mmHg)
Change From Baseline to 26 and 52 Weeks in Blood Pressure
milliliters of mercury (mmHg)1.5 mg LY21892650.75 mg LY2189265Metformin
SBP, 26 weeks (n=244, 251, 239)-1.89 ± 0.89-2.61 ± 0.88-0.91 ± 0.89
SBP, 52 weeks (n=221, 219, 215)-0.11 ± 0.88-2.74 ± 0.88-0.98 ± 0.88
DBP, 26 weeks (n=244, 251, 239)0.05 ± 0.57-1.02 ± 0.56-0.64 ± 0.58
DBP, 52 weeks (n=221, 219, 215)0.31 ± 0.60-1.37 ± 0.59-0.38 ± 0.60
SecondaryPercent Change From Baseline to 26 and 52 Weeks in Total Cholesterol

Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · percentage change in total cholesterol
Percent Change From Baseline to 26 and 52 Weeks in Total Cholesterol
percentage change in total cholesterol1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=244, 244, 243)-3.86 (-10.83 to 5.24)-1.77 (-9.78 to 7.57)-3.51 (-12.19 to 5.45)
52 weeks (n=247, 248, 245)-1.69 (-11.11 to 7.45)-0.78 (-10.02 to 8.10)-3.88 (-12.14 to 5.69)
SecondaryPercentage Change From Baseline to 26 and 52 Weeks in High Density Lipoprotein Cholesterol (HDL-C)

Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · percentage change in HDL-C
Percentage Change From Baseline to 26 and 52 Weeks in High Density Lipoprotein Cholesterol (HDL-C)
percentage change in HDL-C1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=246, 244, 244)2.39 (-4.11 to 13.54)4.20 (-5.66 to 14.66)5.78 (-2.66 to 14.13)
52 weeks (n=248, 248, 246)4.95 (-4.55 to 13.17)2.31 (-5.16 to 12.56)4.32 (-6.56 to 13.64)
SecondaryPercentage Change From Baseline to 26 and 52 Weeks in Low Density Lipoprotein Cholesterol (LDL-C)

Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · percentage change in LDL-C
Percentage Change From Baseline to 26 and 52 Weeks in Low Density Lipoprotein Cholesterol (LDL-C)
percentage change in LDL-C1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=233, 231, 221)-6.86 (-18.26 to 8.20)-2.70 (-15.33 to 9.15)-8.97 (-20.21 to 5.00)
52 weeks (n=236, 240, 231)-2.06 (-15.93 to 9.31)-2.34 (-15.22 to 10.56)-7.23 (-18.56 to 4.36)
SecondaryPercentage Change From Baseline to 26 and 52 Weeks in Triglycerides

Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · percentage change in triglycerides
Percentage Change From Baseline to 26 and 52 Weeks in Triglycerides
percentage change in triglycerides1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks (n=252, 252, 253)-2.35 (-22.32 to 13.61)-1.96 (-21.66 to 22.63)2.56 (-16.00 to 23.79)
52 weeks (n=255, 256, 254)-4.27 (-22.91 to 19.23)-0.86 (-22.31 to 25.37)1.91 (-21.65 to 24.04)
SecondaryChange From Baseline to 26 and 52 Weeks in Pancreatic Enzymes

Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · units per liter (U/L)
Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes
units per liter (U/L)1.5 mg LY21892650.75 mg LY2189265Metformin
Amylase (total), 26 weeks7.00 (2.00 to 13.00)6.00 (0.00 to 13.00)4.00 (-2.00 to 10.00)
Amylase (total), 52 weeks5.50 (-1.00 to 13.00)5.00 (-1.00 to 13.00)4.00 (-2.00 to 9.00)
Amylase (PD), 26 weeks5.00 (2.00 to 9.00)4.00 (1.00 to 7.00)1.00 (-1.00 to 5.00)
Amylase (PD), 52 weeks4.00 (1.00 to 7.00)3.00 (0.00 to 8.00)2.00 (-1.00 to 5.00)
Lipase, 26 weeks7.00 (1.00 to 16.00)5.00 (0.00 to 13.00)1.00 (-4.00 to 8.00)
Lipase, 52 weeks5.00 (-1.00 to 13.00)5.00 (0.00 to 12.00)1.00 (-4.00 to 6.00)
SecondaryChange From Baseline to 26 and 52 Weeks in Serum Calcitonin
Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · picograms per milliliter (pcg/mL)
Change From Baseline to 26 and 52 Weeks in Serum Calcitonin
picograms per milliliter (pcg/mL)1.5 mg LY21892650.75 mg LY2189265Metformin
26 weeks0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
52 weeks0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryNumber of Participants With Treatment Emergent Anti-LY2189265 Antibodies

A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies
participants1.5 mg or 0.75 mg LY2189265
Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies10
SecondaryNumber of Self-reported Hypoglycemic Events at 26 and 52 Weeks

Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and 52 weeks
Reported as:
Number · events
Number of Self-reported Hypoglycemic Events at 26 and 52 Weeks
events1.5 mg LY21892650.75 mg LY2189265Metformin
Severe, 26 weeks (n=241, 248, 236)000
Severe, 52 weeks (n=214, 217, 199)000
Documented Symptomatic, 26 weeks (n=241, 248, 236)262
Documented Symptomatic, 52 weeks (n=214, 217, 199)782
Asymptomatic, 26 weeks (n=241, 248, 236)19913
Asymptomatic, 52 weeks (n=214, 217, 199)599
SecondaryRate of Self-reported Hypoglycemic Events at 52 Weeks

Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \[mg/dL\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Mean · events per participant per year
Rate of Self-reported Hypoglycemic Events at 52 Weeks
events per participant per year1.5 mg LY21892650.75 mg LY2189265Metformin
Severe0.00 ± 0.000.00 ± 0.000.00 ± 0.00
Documented Symptomatic0.62 ± 8.910.15 ± 0.720.09 ± 0.50
Asymptomatic0.24 ± 1.260.30 ± 1.850.18 ± 0.79
SecondaryNumber of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks plus 30-day follow up
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up
participants1.5 mg LY21892650.75 mg LY2189265Metformin
Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up000
SecondaryNumber of Participants With Adjudicated Cardiovascular Events at 52 Weeks Plus 30-day Follow up

Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks plus 30-day follow up
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks Plus 30-day Follow up
participants1.5 mg LY21892650.75 mg LY2189265Metformin
Any CV Event121
Any Fatal CV Event000
Any Nonfatal CV Event121
SecondaryMeasurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)

Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

Time frame:
4 weeks, 13 weeks, 26 weeks, and 52 weeks
Reported as:
Mean · nanogram hours per milliliter (ng*hr/mL)
Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)
nanogram hours per milliliter (ng*hr/mL)1.5 mg LY21892650.75 mg LY2189265
Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)12036 ± 53855919 ± 1548

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg LY2189265—15/269 (5.6%)177/269 (65.8%)
0.75 mg LY2189265—20/270 (7.4%)178/270 (65.9%)
Metformin—16/268 (6%)170/268 (63.4%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
Event1.5 mg LY21892650.75 mg LY2189265Metformin
Chest painGeneral disorders0/2693/2700/268
OsteoarthritisMusculoskeletal and connective tissue disorders1/2692/2700/268
SyncopeNervous system disorders0/2692/2700/268
Ovarian fibromaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1550/1521/147
PregnancyPregnancy, puerperium and perinatal conditions1/1550/1520/147
Angina pectorisCardiac disorders0/2690/2701/268
Atrial fibrillationCardiac disorders0/2690/2701/268
Cardiac failure congestiveCardiac disorders0/2690/2701/268
Pericardial effusionCardiac disorders0/2690/2701/268
Abdominal painGastrointestinal disorders0/2690/2701/268
Most frequent other events
Showing 10 of 16
Most frequent other events
Event1.5 mg LY21892650.75 mg LY2189265Metformin
NauseaGastrointestinal disorders53/26931/27043/268
DiarrhoeaGastrointestinal disorders31/26926/27039/268
NasopharyngitisInfections and infestations14/2699/27028/268
VomitingGastrointestinal disorders26/26920/27014/268
HeadacheNervous system disorders10/26914/27020/268
ConstipationGastrointestinal disorders18/26912/2703/268
Decreased appetiteMetabolism and nutrition disorders18/26912/27012/268
Upper respiratory tract infectionInfections and infestations16/26917/2708/268
Abdominal distensionGastrointestinal disorders13/26913/27010/268
Back painMusculoskeletal and connective tissue disorders5/2699/27012/268

Baseline characteristics

Participants who received at least 1 dose of LY2189265 or Metformin.

Age, Continuous
Age, Continuous(years)1.5 mg LY21892650.75 mg LY2189265MetforminTotal
Mean55.51 ± 10.3855.90 ± 10.6855.26 ± 10.1055.56 ± 10.38
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg LY21892650.75 mg LY2189265MetforminTotal
Female155152147454
Male114118121353
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.5 mg LY21892650.75 mg LY2189265MetforminTotal
Hispanic or Latino908795272
Not Hispanic or Latino179183173535
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg LY21892650.75 mg LY2189265MetforminTotal
American Indian or Alaska Native29282885
Asian21202061
Native Hawaiian or Other Pacific Islander0011
Black or African American17221453
White201198201600
More than one race1247
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)1.5 mg LY21892650.75 mg LY2189265MetforminTotal
United States778074231
Slovakia89926
Finland35412
Spain12111235
United Kingdom0112
India911929
France12121337
Czech Republic109827
Mexico24252372
Canada1091130
Puerto Rico14101539
Argentina27272680
Poland76518
Brazil2237
Croatia34411
Romania14131340
South Africa12111235
Germany22212164
Korea, Republic of34512
Body Weight
Body Weight(kilograms (kg))1.5 mg LY21892650.75 mg LY2189265MetforminTotal
Mean92.67 ± 18.7991.79 ± 18.6792.40 ± 19.2392.28 ± 18.87
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))1.5 mg LY21892650.75 mg LY2189265MetforminTotal
Mean33.66 ± 5.6533.08 ± 5.8433.05 ± 5.0633.26 ± 5.53
Duration of Diabetes
Duration of Diabetes(years)1.5 mg LY21892650.75 mg LY2189265MetforminTotal
Mean2.65 ± 1.502.60 ± 2.172.63 ± 1.772.63 ± 1.83

1 further baseline measures are reported on the registry.

08

Study locations

91 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85018, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buena Park, California 90620, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Burbank, California 91505, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Redlands, California 92374, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Mateo, California 94401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33316, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32822, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30303, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gurnee, Illinois 60031, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40217, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Southfield, Michigan 48075, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14609, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Raleigh, North Carolina 27609, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Eugene, Oregon 97404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beaver, Pennsylvania 15009, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johnstown, Pennsylvania 15905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Levittown, Pennsylvania 19056, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78749, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Georgetown, Texas 78626, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23233, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olympia, Washington 98502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Selah, Washington 98942, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99208, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1188AAF, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Isidro, B1642DCD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fortaleza, 60430-350, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 04020-041, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kelowna, British Columbia V1Y 1Z9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, British Columbia V5Z 3J5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R2V 4W3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halifax, Nova Scotia B3H 1V7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M9W 4L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1H1Z1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dubrovnik, 20000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osijek, 31000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Slavonski Brod, 35000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zagreb, 10000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beroun, 26601, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Novy Jicin, 74101, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 149 00, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nurmijarvi, 01900, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oulu, 90100, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Bouexiere, 35340, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Murs Erigne, 49610, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44300, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vieux Conde, 59690, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gebhardshain, 57580, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55116, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Münster, 48145, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neunkirchen, 66539, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Potsdam, 14469, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560003, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chennai, 600029, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400053, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagpur, 440020, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucheon, 420-717, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 136 705, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suwon-City, 442-723, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 6700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64461, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampico, 89000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-242, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-091, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 50-349, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carolina, 00983, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manati, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00987, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 020359, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cluj-Napoca, 400006, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Galati, 800587, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Resita, 320076, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Banska Bystrica, 97405, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bratislava, 821 03, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trebisov, 07501, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halfway House, 1685, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kempton Park, 1619, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Somerset West, 7130, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Begonte, 27373, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Granada, 18012, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seville, 41003, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Penzance, Cornwall TR19 7HX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, County Durham DH1 2QW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Greater London W9 1SP, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cleveleys, Lancashire FY5 3LF, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Crawley, RH10 7DX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nottingham, NG3 7DQ, United Kingdom
09

References and documents

Publications

  • Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2. PubMed 32501595 ↗
  • Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7. PubMed 27161178 ↗
  • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4. PubMed 26691396 ↗
  • Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014 Aug;37(8):2168-76. doi: 10.2337/dc13-2759. Epub 2014 May 19. PubMed 24842985 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Nov 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 2 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2010
First posted
May 19, 2010
Start
May 2010
Primary completionActual
Nov 2011
CompletionActual
Jun 2012
Results delay requested
May 24, 2012
Results first posted
Jan 16, 2015
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01126580
Responsible party
Sponsor
First posted
May 19, 2010
Start date
May 2010
Primary completion
Nov 2011
Completion
Jun 2012
Results posted
Jan 16, 2015
Last update
Jan 16, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion